Evidence map›Paper›PMID 25469010›Full record

ReviewWorld journal of gastroenterology2014

Rationale for the potential use of mesenchymal stromal cells in liver transplantation.

Morgan Vandermeulen, Céline Grégoire, Alexandra Briquet, Chantal Lechanteur, Yves Beguin, Olivier Detry

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Mesenchymal stem cells prolong the survival of orthotopic liver transplants by regulating the expression of TGF-β1.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Morgan VandermeulenMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.
Céline GrégoireMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.
Alexandra BriquetMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.
Chantal LechanteurMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.
Yves BeguinMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.
Olivier DetryMorgan Vandermeulen, Olivier Detry, Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, B4000 Liege, Wallonia, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) are multipotent and self-renewing cells that reside essentially in the bone marrow as a non-hematopoietic cell population, but may also be isolated from the connective tissues of most organs. MSCs represent a heterogeneous population of adult, fibroblast-like cells characterized by their ability to differentiate into tissues of mesodermal lineages including adipocytes, chondrocytes and osteocytes. For several years now, MSCs have been evaluated for their in vivo and in vitro immunomodulatory and 'tissue reconstruction' properties, which could make them interesting in various clinical settings, and particularly in organ transplantation. This paper aims to review current knowledge on the properties of MSCs and their use in pre-clinical and clinical studies in solid organ transplantation, and particularly in the field of liver transplantation. The first available clinical data seem to show that MSCs are safe to use, at least in the medium-term, but more time is needed to evaluate the potential adverse effects of long-term use. Many issues must be resolved on the correct use of MSCs. Intensive in vitro and pre-clinical research are the keys to a better understanding of the way that MSCs act, and to eventually lead to clinical success.

Indexed as

AnimalsCell DifferentiationCell LineageCell ProliferationGraft SurvivalHepatocytesHumansLiverLiver RegenerationLiver TransplantationMesenchymal Stem Cell TransplantationComplicationImmunosuppressionMesenchymal stem cellsOrgan transplantationTolerance

Identifiers

PMID25469010
PMCPMC4248185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.